Recursion's share price has dropped in recent weeks due to poor clinical trial data ... full-stack technology-enabled platform spanning patient-centric target discovery, structure-based drug ...

their shape and structure. Recursion has gotten some substantial funding for that very large data science project. It recently scored $121 million in venture money in a Series C round led by ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...